Trials / Unknown
UnknownNCT03905967
TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC
Transarterial Chemoembolization With Lenvatinib Versus Lenvatinib Alone in First-line Treatment of Advanced Hepatocellular Carcinoma: a Phase III, Multicenter, Randomized Controlled Trial
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 336 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is is an open label, multicenter, randomized controlled phase 3 clinical trial. The purpose is to compare the efficacy and safety of lenvatinib plus TACE with lenvatinib alone for advanced HCC patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | TACE | TACE will be performed one day after oral administration of lenvatinib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of each center. |
| DRUG | Lenvatinib | Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients \<60kg, and 12 mg qd for patients \>60kg) |
Timeline
- Start date
- 2019-06-16
- Primary completion
- 2023-04-15
- Completion
- 2023-06-15
- First posted
- 2019-04-08
- Last updated
- 2019-08-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03905967. Inclusion in this directory is not an endorsement.